A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age8-18
SponsorHugo W. Moser Research Institute at Kennedy Krieger, Inc.

About this trial

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are:

Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo?

Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD.

Participants will:

* Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

clinically diagnosed with ADHD

have blood ferritin level below 50ng/mL

have parent- or self-reported restless sleep

Disqualifiers

presence of any chronic medical or genetic condition that could impact iron metabolism

presence of moderate to severe Obstructive Sleep Apnea

having received Iron supplementation treatment within the past 3 months

having blood ferritin level indicative of anemia that requires immediate treatment

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ferrous Sulfate

    Dietary supplement

    Dosing of the iron supplement will be based on weight.

  • Placebo

    Other intervention

    Placebo pills will be provided to participants in the placebo arm

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Iron supplementation armExperimental treatment 1 intervention
Group B: Placebo armPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Sleep Efficiency

Sleep efficiency refers to the proportion of time in bed spent sleeping and is measured via actigraphy monitoring. Higher scores indicate more efficient/better sleep.

Time frame
Sleep efficiency will be assessed nightly for 2 weeks before treatment begins and then again for 2 weeks at the end of treatment.

Secondary outcomes

1

Total sleep time

Total sleep time in minutes as measured by actigraphy. Higher scores indicate more time asleep.

Time frame
These will be assessed nightly for a period of 2 weeks before treatment begins and then again for 2 weeks at the end of treatment.
2

Wake after sleep onset

Number of minutes spent awake between falling asleep at night and getting up in the morning, as measured by actigraphy. Higher scores on this measure are indicative of greater difficulty staying asleep through the night.

Time frame
These will be assessed nightly for a period of 2 weeks before treatment begins and then again for 2 weeks at the end of treatment.
3

Latency to sleep onset

Number of minutes from laying down in bed for the night to falling asleep, measured by actigraphy. Higher scores on this measure will indicate longer times to fall asleep.

Time frame
Assessed nightly for a period of 2 weeks before treatment begins and then again for 2 weeks at the end of treatment.
4

Attention Deficit Hyperactivity Disorder-Rating Scale-V, parent version

Parent rating of child's ADHD symptoms; raw scores will be calculated by summing all items and will range from 0-54; higher scores indicate more severe ADHD symptoms.

Time frame
Completed at baseline and again within 2 weeks post-treatment.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: